Premium
Double Crown‐Retained Maxillary Overdentures: 5‐Year Follow‐Up
Author(s) -
Frisch Eberhard,
Ziebolz Dirk,
RatkaKrüger Petra,
Rinke Sven
Publication year - 2015
Publication title -
clinical implant dentistry and related research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.338
H-Index - 85
eISSN - 1708-8208
pISSN - 1523-0899
DOI - 10.1111/cid.12087
Subject(s) - crown (dentistry) , dentistry , orthodontics , medicine
Background There is a lack of data concerning implant‐supported overdentures ( IODs ) retained by double crowns in the edentulous maxilla. Purpose To perform a retrospective evaluation of clinical outcomes (survival/success rates) of maxillary overdentures retained on four implants via double crowns. Material and Methods Between 1993 and 2011, 28 patients with edentulous maxillae were restored with overdentures supported by four implants with a M orse taper connection ( A nkylos, D entsply F riadent, M annheim, G ermany) and double crowns according to the M arburg D ouble C rown ( MDC ) technique in a private practice. For retrospective evaluation of implant and prosthetic survival (in situ criterion) and success (event‐free observational period), only patients attending a professional maintenance program were included ( n = 20). Results Twenty patients (13 female/ seven male, mean age: 63.45 ± 7.18 years) with 80 implants met the inclusion criteria. The mean follow‐up period was 5.64 ± 3.50 years. One implant was lost (cumulative survival rate: 98.75%). Eight implants (10.1%) in two patients (10%) showed peri‐implantitis; both patients were active smokers (cumulative success rate: 88.75%). All dentures were still functional (prosthetic survival rate 100%) at the time of investigation. Technical maintenance procedures (e.g., abutment loosening, screw loosening, acrylic fracture or relining) were required at a rate of 0.222/patient‐year. Conclusions Within the limitations of this study, we conclude that MDC ‐ IODs are a promising treatment alternative for edentulous maxillae offering high implant and prosthesis survival rates > 98% and a limited incidence of biological and technical complications after a mean observational period of >5 years.